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Objectives. This prospective, multicenter trial was aimed at
defining efficacy and safety of low energy shocks during atrial
fibrillation in a diverse cohort of patients.
Background. Experimental studies in sheep and preliminary
data in humans have suggested that low energy internal shocks
delivered between right atrial and coronary sinus electrode cath-
eters may terminate atrial fibrillation.
Methods. Biphasic 3/3-ms R wave synchronous shocks were
delivered between two electrode catheters in the right atrium and
coronary sinus. The defibrillation protocol started with a test
shock of 20 V, and shocks increased in 40-V steps until restoration
of sinus rhythm or a maximum of 400 V. Shock delivery was
withheld after short RR intervals. In 141 patients with atrial
fibrillation, the protocol was carried out under sedation in case
the shock was associated with discomfort. The atrial arrhythmia
was paroxysmal (<27 days) in 50 patients, chronic (>30 days) in
53, intermediate (>7 days, <230 days) in 18 and induced in 20.
Underlying heart disease was present in 88 patients (62%).
Results. Paroxysmal atrial fibrillation was successfully termi-
nated in 46 (92%) of 50 patients, chronic atrial fibrillation in 37
(70%) of 53, intermediate in 16 (89%) of 18 and induced in 16
(80%) of 20. Mean conversion threshold was 1.8 J (213 V) in the
induced group, 2.0 J (229 V) in the paroxysmal group, 2.8 J
(272 V) in the intermediate group and 3.6 J (311 V) in the chronic
group. The conversion voltage was significantly (p < 0.001) higher
in the chronic group than in the other groups of atrial fibrillation
and increased significantly with the duration of atrial fibrillation
and with left atrial size (p < 0.05). Of 1,779 R wave synchronized
shocks delivered with a mean (6SD) preceding RR interval of
676 6 149 ms, no ventricular arrhythmia was induced. The latter
may occur after unsynchronized shocks.
Conclusions. Low energy transvenous shocks in patients with
atrial fibrillation are effective and safe, provided that shocks are
properly synchronized to R waves with preceding RR intervals
that meet appropriate cycle length criteria. This study provides
data that may be useful in the development of an implanted atrial
defibrillator.
(J Am Coll Cardiol 1997;29:750–5)
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Atrial fibrillation, an extremely common arrhythmia, is esti-
mated to occur in 2% to 4% of the general population .65
years old (1). The incidence is even higher in patients with
underlying heart disease. Atrial fibrillation may be associated
with symptoms, hemodynamic impairment of cardiac function
and an increased risk of cerebrovascular and systemic throm-
boembolism (2). Antiarrhythmic drug therapy is widely pre-
scribed to prevent recurrence of atrial fibrillation. As pointed
out by Antman et al. (3), the benefits of treatment with
conventional antiarrhythmic agents have not been demon-
strated in large-scale, randomized clinical trials. Although
newer antiarrhythmic agents, such as propafenone, flecainide
or sotalol, seem to be associated with a relatively low incidence
of side effects, the long-term safety of these antiarrhythmic
agents remains to be evaluated (3). Conversion to sinus rhythm
represents the ideal end point of therapy for patients with
persistent, non–self-terminating atrial fibrillation because it
should restore both normal hemodynamic function and a
slower heart rate. Restoring sinus rhythm may eliminate
symptoms, reduce thromboembolic complications, improve
exercise capacity and most likely improve survival. Recent
observations reported by Wijffels et al. (4) suggest that atrial
fibrillation may cause electrophysiologic changes of the atrial
myocardium that favor the perpetuation of atrial fibrillation. In
their goat model of atrial fibrillation, the increase in duration
of the arrhythmia was associated with a shortening of the atrial
effective refractory period. Therefore, prompt termination of
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atrial fibrillation is desirable before these changes take place or
become irreversible.
Introduced 30 years ago and popularized by Lown (5),
external electrical cardioversion is an effective and safe treat-
ment for restoring sinus rhythm. Internal cardioversion was
shown to be an alternative therapy in patients with failed
external cardioversion (6,7). Both techniques require high
energy shocks and general anesthesia. After the report of
Cooper et al. (8) showing that pacing-induced atrial fibrillation
in sheep may be successfully cardioverted with low energy
shocks delivered between the right atrium and the coronary
sinus, there have been isolated attempts to terminate atrial
fibrillation in humans. However, limited data are available on
the efficacy of low energy internal cardioversion in patients
with long-standing atrial fibrillation (9,10) and no data on
diverse populations of patients.
The objective of the present prospective, multicenter study
was to evaluate the efficacy and safety of biphasic shocks
applied between right atrial and coronary sinus electrode
catheters in different subsets of patients with atrial fibrillation.
A previous report (10) described the feasibility of low energy
shocks in 19 patients with induced atrial fibrillation. The
present report provides the data for 141 patients and includes
patients with spontaneous as well as induced atrial fibrillation.
Methods
Study patients. This prospective study included six centers:
Queen Mary Hospital in Hong Kong, St. George’s Hospital in
London, University of Ghent in Ghent, Centre Hospitalier
Universitaire Vaudois in Lausanne, OLVHospital in Aalst and
Centre Hospitalier et Universitaire Hoˆpital Nord in Marseille.
Entry criteria included 1) age .18 years; 2) an indication for
cardioversion, including patients with failed external cardio-
version and those with atrial fibrillation induced in the elec-
trophysiologic laboratory in the course of another study; 3)
written informed consent obtained; 4) adequate oral anticoag-
ulation with warfarin or a similar agent, for a minimum of 3
weeks or subcutaneous or intravenous heparin for a minimum
of 3 days and absence of thrombus on the transesophageal
echocardiogram. Patients were excluded from the study if one
or more of the following conditions were present: 1) history of
cerebrovascular accident; 2) atrial fibrillation resulting from an
acute or subacute illness or uncontrolled congestive heart
failure; 3) ejection fraction ,20%; 4) patients with docu-
mented or suspected thrombus in the left atrial or ventricular
chambers. Patients with atrial fibrillation were classified into
four groups: paroxysmal, chronic, intermediate and induced.
Paroxysmal atrial fibrillation was defined as attacks of arrhyth-
mia lasting ,7 days and separated by periods of normal sinus
rhythm. Chronic atrial fibrillation was defined as atrial fibrilla-
tion lasting .30 days. Atrial fibrillation was said to be inter-
mediate if it lasted .7 days and #30 days. Induced atrial
fibrillation was atrial fibrillation occurring in the course of an
electrophysiologic study and mechanically or electrically in-
duced. Whenever appropriate, antiarrhythmic therapy was
discontinued for 5 half-lives. However, the presence of antiar-
rhythmic therapy was not an exclusion criterion. All patients
underwent a workup, including history and physical examina-
tion, 12-lead electrocardiography, chest radiography, 24-h am-
bulatory monitoring, M-mode and two-dimensional echocardi-
ography, laboratory tests (creatinine, serum potassium, red
blood count) and thyroid function evaluation. The protocol
received approval from the ethical committee of each partici-
pating center.
Protocol design. The protocol consisted of biphasic 3/3-ms
shocks (Fig. 1) delivered from a custom external atrial defi-
brillator having a single 80-mF capacitor and a maximal output
of 400 V (XAD InControl Inc.). Shocks were delivered
through two 6F temporary electrode catheters with nine poles
of ;2.8-cm2 surface area each (Elecath). One electrode was
positioned in the right atrium such that the electrodes had
contact with the anterolateral wall. The other electrode was
positioned in the coronary sinus. The right atrial catheter
served as the cathode and the coronary sinus catheter as the
anode. The external atrial defibrillator allowed the user to
program leading-edge voltage and minimal RR interval, after
which a shock could be delivered. After each shock, the
defibrillator depicted the voltage, energy and impedance. R
wave synchronization signals were obtained from electrophysi-
ologic laboratory monitors and achieved through a variety of
external synchronization systems, not usually with an im-
planted ventricular lead. Cardioversion was performed under
local anesthesia, in the fasting state, and, whenever needed,
conscious sedation was provided. The defibrillation protocol
included a single conversion and an initial test shock of 20 V;
the energy was then increased in 40-V steps until restoration of
sinus rhythm or a maximum of 400 V. One shock was given at
each voltage level, and shocks were withheld after short RR
intervals (,300 ms). Whenever possible, the RR interval
Figure 1. Electrode configuration. Anteroposterior chest radiograph
showing an electrode catheter in right atrium (RA) and coronary sinus
(CS).
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preceding shock was set at$500 ms. It was recommended that,
after restoration of sinus rhythm, oral anticoagulation be
prescribed for a minimum of 1 month.
Statistical analysis. All statistic analyses were performed
using Statview 4.5. Regression tests were done by both multiple
and stepwise regression. Creatine kinase analysis was done by
analysis of variance (ANOVA). Differences between groups
were analyzed by unpaired t test after analysis of variance, and,
when needed, nonparametric tests were performed. For left
atrial size, the Fisher test was used for comparison between
groups.
Results
Clinical characteristics of patients. A total of 153 patients
were eligible for the trial, 12 of whom were excluded from
cardioversion analysis because the primary rhythm was flutter
in 2, and the left-sided lead was placed in the pulmonary artery
in 10 because the coronary sinus could not be catheterized.
One hundred forty-one patients (103 men, 38 women; mean
[6SD] age 58 6 13 years, range 18 to 87) were therefore
enrolled in the trial. Structural heart disease was detected in 54
patients (38%) and included hypertension in 21, cardiomyop-
athy in 10, valvular heart disease in 15, coronary artery disease
in 6 and congenital abnormality in 5. No heart disease was
reported in 87 patients (62%). Fifty patients (35%) were
classified as having paroxysmal, 53 (37%) chronic, 18 (13%)
intermediate and 20 (14%) induced atrial fibrillation. The
clinical characteristics of the four groups of patients are shown
in Table 1. The mean age of all groups together was signifi-
cantly different from that of each individual group (p , 0.01),
except for the chronic and paroxysmal groups whose mean
ages were similar. Body surface area was significantly different
in the induced group compared with the chronic or paroxysmal
groups. Left atrial diameter was significantly different in the
chronic (44 6 7 mm) versus the induced group (35 6 5 mm),
the chronic versus the paroxysmal (39 6 7 mm) group and the
intermediate (42 6 5 mm) versus the induced group.
Response to transvenous cardioversion. In response to the
defibrillation protocol, 115 (82%) of the 141 patients had
restoration of sinus rhythm with a mean of 12.4 shocks/patient
(range 3 to 38). An example of successful termination of atrial
fibrillation using a low energy shock is shown in Figure 2. As
shown in Table 2, paroxysmal atrial fibrillation was terminated
in 46 (92%) of 50 patients with a mean conversion voltage of
229 V and a mean conversion energy of 2.0 J (range 0.3 to 4.4).
Chronic atrial fibrillation was terminated in 37 of 50 patients
with a mean conversion voltage of 311 6 60 V and a mean
conversion energy of 3.6 J (range 0.6 to 6.2). Intermediate
atrial fibrillation was reverted to sinus rhythm in 16 (89%) of
18 patients with a mean conversion voltage of 272 V and a
mean conversion energy of 2.8 J (range 1.1 to 4.4). In the
induced atrial fibrillation group, sinus rhythm was restored in
16 of 20 patients with a mean conversion voltage of 213 V and
a mean energy of 1.8 J (range 0.3 to 4.3). The defibrillation
impedance, calculated as the mean of the impedances mea-
sured after each shock and for each patient, did not show any
significant difference between the four groups of patients.
Safety. A total of 1,779 shocks were delivered to the 141
patients, with a mean preceding RR interval of 676 6 149 ms
(Table 3). No complications were observed after R wave
synchronized shocks. Creatine kinase enzyme levels measured
before (806 52 IU), immediately after (826 49 IU) and 2 and
6 h after reversion to sinus rhythm (89 6 59 and 90 6 66 IU,
Figure 2. Successful termination of atrial fibrillation after low energy
transvenous cardioversion. The leading edge voltage was 260 V and the
energy 2.6 J. Note that in this case the proper synchronization signal
(S) was obtained from the surface electrocardiogram.
Table 1. Clinical Characteristics of 141 Patients
Paroxysmal
AF Group
(n 5 50)
Chronic
AF Group
(n 5 53)
Intermediate
AF Group
(n 5 18)
Induced
AF Group
(n 5 20)
Age (yr) 58 6 12 58 6 11 69 6 14 49 6 11
M/F 40/10 42/11 10/8 11/9
BSA (m2) 1.91 6 0.21 1.88 6 0.20 1.75 6 0.24 1.72 6 0.23
AF duration (days) 1.27 6 1.92 458 6 568 17.2 6 6.7 NA
LA diameter (mm) 38 6 8 45 6 87 42 6 5 36 6 5
Heart disease present/absent 22/28 19/34 8/10 5/15
Antiarrhythmic agents 18 8 6 4
Data presented are mean value 6 SD or number of patients. AF 5 atrial fibrillation; BSA 5 body surface area; F 5
female; LA 5 left atrial; M 5 male; NA 5 not applicable.
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respectively) or completion of the defibrillation protocol, did
not show any significant increase. No other evidence of cardiac
injury including monitoring of the electrocardiogram after
shocks, was seen during the study.
Sedation. Of 141 patients, 50 received sedation at the start
of the study, and 91 were not sedated. Of these 91 patients,
sedation was needed at some point in 53 because of patient
discomfort.
Variables affecting the results. When variables that may
affect conversion voltage were examined, type of atrial fibril-
lation, duration of atrial fibrillation and size of the left atrium
were significant. The conversion voltage required to terminate
atrial fibrillation in the chronic group was significantly higher
than that in the paroxysmal or the induced group (p , 0.001)
(Fig. 3). There was no significant difference in successful
conversion voltage in the chronic group between patients with
atrial fibrillation established ,90 days (11 patients) and those
with atrial fibrillation established .3 months. There was a
significant relation between conversion voltage and duration of
atrial fibrillation or left atrial diameter (p , 0.05). However,
the correlation coefficients for these two variables were low.
The variables that were found not significantly related to
conversion voltage were age, height, weight, previous RR
interval and body surface area.
Although reproducibility was not tested in this study, three
patients underwent repeat cardioversion after attaining sinus
rhythm. The mean conversion energy changed from 5.8 to
2.5 J.
Discussion
Background. Synchronized electrical cardioversion re-
mains the most successful and the safest treatment for rees-
tablishing sinus rhythm in patients with atrial fibrillation (5,12).
It is commonly achieved using anterolateral paddle placement
or anteroposterior paddle placement on the thorax and deliv-
ering $100-J shocks under general anesthesia. Although the
overall success of external cardioversion is reported to be high
(5), this technique may fail in a number of patients (7). Among
the factors likely to affect the results, transthoracic impedance,
energy level and paddle position have been implicated (13,14).
Le´vy et al. (6) reported successful cardioversion of chronic
atrial fibrillation using shocks delivered between an electrode
catheter in the right atrium (cathode) and a back plate (anode)
in patients with failed external cardioversion. This technique
used energy of 200 or 300 J under general anesthesia. Previous
attempts to terminate atrial fibrillation by delivering intracar-
diac shocks in the right atrium with low energies have been
disappointing. Dunbar et al. (15) achieved termination of only
26% of episodes of atrial fibrillation with energies ,5 J in a
model of talc-induced pericarditis in dogs. Nathan et al. (16),
using a similar technique, were unsuccessful in terminating
atrial fibrillation in patients. Both studies used a catheter
(Medtronic 6880) with the anode and cathode on the same
catheter. A different approach was taken by Kumagai et al.
(17), who used a technique in dogs comparable to that used by
Le´vy et al. (6) and were able to successfully terminate atrial
fibrillation with monophasic shocks of 1 J in 70% of attempts.
Cooper et al. (8) found that in an experimental model of
pacing-induced atrial fibrillation in sheep, the electrode con-
figuration that resulted in the lowest energy requirement
comprised catheters in the right atrial appendage and coronary
sinus. In their studies, biphasic shocks resulted in the lowest
defibrillation energy requirements of the waveforms tested.
Figure 3. Conversion voltage and type of atrial fibrillation. Chronic
atrial fibrillation required significantly higher conversion voltages than
other types of atrial fibrillation. Intermed. 5 intermediate; PAF 5
paroxysmal atrial fibrillation.
Table 2. Results of Transvenous Low Energy Cardioversion in 141 Patients Included in
Multicenter Trial
AF Group Success
Shock
(V)
Conversion
Threshold
(J)
Impedance
(ohms)
Previous
RR Interval
(ms)
Paroxysmal (n 5 50) 46 (92%) 2296 55 2.0 6 0.97 58 6 9 657 6 145
(100–340) (0.3–4.4) (38–83) (372–982)
Chronic (n 5 53) 37 (70%) 3116 60 3.6 6 1.4 65 6 10 653 6 124
(140–400) (0.6–6.2) (44–85) (500–975)
Intermediate (n 5 18) 16 (89%) 2726 56 2.8 6 1.0 58 6 10 668 6 107
(180–340) (1.1–4.4) (38–78) (500–911)
Induced (n 5 20) 16 (80%) 2136 73 1.8 6 1.3 63 6 11 658 6 189
(100–340) (0.3–4.3) (49–83) (312–964)
Data presented are number (%) of patients or mean value 6 SD (range). AF 5 atrial fibrillation.
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These findings prompted the present multicenter trial aimed at
evaluating the safety and efficacy of biphasic shocks delivered
between the right atrium and coronary sinus electrode cathe-
ters in patients with atrial fibrillation.
Comparison with previous reports. The present study
showed that it was possible to terminate atrial fibrillation in
different subsets of patients with $75% success with a mean
energy ranging from 0.3 to 6.2 J. Alt et al. (9) were successful
in reestablishing sinus rhythm in 10 of 13 patients with chronic
atrial fibrillation with a mean energy of 3.76 1.7 J. Murgatroyd
et al. (11) were able to terminate pacing or mechanically
induced atrial fibrillation in 19 patients, with an energy ranging
from 0.7 to 4.4 J. Only four of their patients had spontaneous
atrial fibrillation. These patients are also part of the present
study. Saksena et al. (10) found high defibrillation thresholds
using different electrode configurations, in particular, a right
atrium to axillary patch electrode (20.1 6 7.4 J). The best lead
configuration resulted in a mean defibrillation threshold of
9.9 6 7.7 J. The present conversion data in 141 patients are
consistent with previous reports using a right atrium to coro-
nary sinus vector and show that regardless of the type of atrial
fibrillation, successful termination may be obtained using low
energy shocks. Furthermore, the study showed that the con-
version voltage required for restoring sinus rhythm in patients
with chronic atrial fibrillation is higher than that required for
other types (i.e., paroxysmal, intermediate or induced) of atrial
fibrillation.
Safety. In this study, no complications occurred after 1,779
R wave synchronized shocks. It should be emphasized that
according to the defibrillation protocol, shocks were generally
withheld after short RR intervals (,500 ms). The latter was
based on the experimental work of Ayers et al. (18) who
showed that synchronized shocks delivered after short RR
intervals (,300 ms) were associated with an increased risk of
induction of rapid ventricular tachycardia or fibrillation. Mur-
gatroyd et al. (19) compiled the experience of a number of
different centers evaluating transvenous low energy atrial
fibrillation and observed no ventricular tachyarrhythmias in a
total of 1,212 shocks. The mean preceding RR interval was
619 6 214 ms, similar to that of 676 6 149 ms found in the
present trial. However, they observed transient bradycardia
and occasional pauses (#6,280 ms), suggesting that synchro-
nized shocks delivered by an implanted atrial defibrillator
would require antibradycardia support pacing. The cases ana-
lyzed by Murgatroyd et al. (19) included only the partial
experience of two of the centers that participated in the
present study. We observed a ventricular proarrhythmia in a
patient with flutter after an unsynchronized shock due to a
faulty synchronization on the T wave. Ventricular tachycardia
rapidly degenerating into ventricular fibrillation occurred. Si-
nus rhythm was restored after prompt external cardioversion.
A similar case was reported by Falk and Podrid (12) after an
attempted external cardioversion of atrial flutter and improper
synchronization, resulting in a delivered shock on the T wave
and ventricular fibrillation. Saksena et al. (11) observed non-
sustained polymorphic ventricular tachycardia after a poorly
synchronized shock, also in a patient with flutter. Although
rare, the possibility of such a serious event emphasizes the
importance of R wave synchronization, hence requiring a lead
placed in the right ventricle for an implanted atrial defibrilla-
tor.
Clinical applications. Low energy transvenous cardiover-
sion has a number of clinical applications that may be classified
into two types:
1. Cardioversion using an external device and temporary
electrode catheters may have a number of potential applica-
tions. It may be used to terminate pacing or catheter-induced
atrial fibrillation complicating an electrophysiologic study. Low
energy transvenous cardioversion does not require general
anesthesia, and only mild sedation using midazolam may be
needed. This technique may be used to repeatedly terminate
recurrent atrial fibrillation in intensive care units, particularly
after open heart surgery. High energy internal cardioversion
has been suggested as an option in patients with failed external
cardioversion (6,7,20,21). Low energy cardioversion may be an
alternative in patients with high transthoracic impedance, such
as obese patients or patients with chronic obstructive lung
disease.
2. Low energy cardioversion may have an application in
implanted devices. In the ventricular implantable cardioverter-
defibrillators, atrial fibrillation is often responsible for inap-
propriate shocks. The latter may even be responsible for
ventricular proarrhythmia. Proper detection and termination
of atrial fibrillation may be a useful addition to currently
available implantable cardioverter-defibrillators in patients
with malignant ventricular arrhythmias. Moreover, our results
on the safety and efficacy of low energy transvenous cardiover-
sion support the feasibility of an implanted atrial defibrillator.
Such a device may widen the scope of nonpharmacologic
therapy of atrial fibrillation and may be an alternative therapy
to ablation of the atrioventricular node and pacemaker implan-
tation. The efficacy of low energy cardioversion demonstrated
in this study indicates that there may be a subgroup of patients
with atrial fibrillation who may benefit from an implanted
atrial defibrillator, provided that the safety and tolerability of
such device are proved by appropriately conducted clinical
trials. In three patients who required repeated cardioversion,
the mean conversion energy was lower, which suggests that
periods of sinus rhythm may induce remodeling of the atria.
More data are needed to support such hypothesis in patients.
Study limitations. Although the present report provides
information on the safety and feasibility of low energy trans-
venous cardioversion of atrial fibrillation, it does not address a
number of issues. As pointed out by Murgatroyd et al. (10), the
energy required to restore sinus rhythm with the defibrillation
protocol used does not represent a defibrillation threshold.
Cardioversion may result from a cumulative energy due to
previous ineffective shocks. The same limitation applies to the
so-called ventricular defibrillation threshold. The protocol of
this trial was not intended to test the reproducibility after a
successful shock. Although the protocol included the evalua-
tion of shock-related discomfort, it appeared difficult to
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present meaningful data for a number of reasons. The type and
time at which sedation should be used were left to the
judgment of the investigator and to the consent obtained from
the patient to undergo the protocol without sedation. In the
Marseille experience, only 30 of 42 patients agreed to undergo
the protocol without sedation. In contrast, it would be inap-
propriate to lump together the data on pain from five countries
over two continents using a subjective scale because the
perception of pain may well be cultural. The issue of pain
should be evaluated separately in a specially designed protocol.
Conclusions. This prospective, multicenter trial on low
energy transvenous cardioversion of atrial fibrillation showed,
in a total of 141 patients, that shocks delivered between two
electrode catheters in the right atrium and coronary sinus are
effective in restoring sinus rhythm. This technique is safe,
provided that shocks are synchronized to the R wave with
preceding RR intervals that meet appropriate cycle length
criteria. Unsynchronized shocks present the risk of ventricular
proarrhythmia. Although the technique was successful in re-
storing sinus rhythm in 82% of patients, the conversion voltage
required was significantly higher in patients with chronic atrial
fibrillation than those with other types of atrial fibrillation and
increased with the duration of atrial fibrillation and left atrial
size. The procedure does not require general anesthesia and
may be useful in terminating persistent atrial fibrillation in a
number of clinical situations. This study provides important
data pertinent to the potential use of an implanted atrial
defibrillator.
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